跳到正文
Advanced Functional Materials· Yang·· 8 天前AI 评分40

AI从头设计的肽功能化纳米颗粒调控脂质代谢改善MASH

De Novo AI‐Designed Peptide‐Functionalized Nanoparticles Modulate Lipid Metabolism to Ameliorate Metabolic Dysfunction–Associated Steatohepatitis

AI 导读

研究开发了AI从头设计的脂质转运抑制剂AILITIX,并构建表面功能化AILITIX与ICG、负载isoquercitrin和obeticholic acid的超声响应肝靶向脂质体纳米颗粒;体外实验显示isoquercitrin直接结合并抑制ACSL4活性,纳米颗粒抑制mTOR、ULK1、TFEB磷酸化以激活自噬。

AI 深度导读基于原文整理的分节解读
背景
MASH 以肝脏甘油三酯过量堆积为特征,长链脂肪酸(LCFAs)是 TG 的关键前体,CD36 负责把 LCFAs 转运进肝细胞。早期 MASH 目前缺少有效的药物治疗手段。
做法
作者用 AI 从头设计出脂质转运抑制剂 AILITIX,它能高亲和结合 CD36 并抑制 CD36 介导的脂肪酸摄取。随后把 AILITIX 与吲哚菁绿(ICG)修饰在超声响应、肝靶向的脂质体纳米粒表面,并包载异槲皮苷(IQ)与 FXR 激动剂奥贝胆酸(OCA)。体外实验显示 IQ 直接结合并抑制 ACSL4 活性,从而抑制 SREBF1 驱动的从头脂肪生成。
结论
纳米粒抑制 mTOR、ULK1 和 TFEB 的磷酸化,激活自噬通路,促进脂质降解并缓解氧化与线粒体应激。小鼠模型中,治疗协同改善了脂肪变性、氧化损伤和炎症;单细胞转录组显示干预抑制纤维化相关基因表达,并重塑肝脏免疫微环境。
意义
结果提示这套 AI 设计的肽基纳米治疗策略在 MASH 精准治疗上有应用潜力。目前证据来自体外实验与小鼠模型,尚未涉及人体数据。

原文摘要

出版方登记 · Crossref

Metabolic dysfunction–associated steatohepatitis (MASH) is characterized by the excessive accumulation of triglycerides (TG) in the liver, with long‐chain fatty acids (LCFAs) as key TG precursors. CD36, a pivotal transporter, facilitates the uptake of LCFAs into hepatocytes. Currently, there are no effective pharmacological treatments available for early‐stage MASH. To address this, we developed AILITIX, a de novo AI‐designed lipid transport inhibitor. AILITIX exhibits high binding affinity for CD36 and effectively inhibits CD36‐mediated fatty acid uptake. We then synthesized ultrasound‐responsive, liver‐targeted liposomal nanoparticles (NPs) surface‐functionalized with AILITIX and indocyanine green (ICG), and encapsulating the natural flavonoid isoquercitrin (IQ) and the FXR agonist obeticholic acid (OCA). In vitro assays demonstrated that IQ directly binds to and inhibits ACSL4 activity, thereby suppressing SREBF1‐driven de novo lipogenesis. Furthermore, the NPs inhibited the phosphorylation of mTOR, ULK1, and TFEB, activating the autophagy pathway, enhancing lipid degradation, and alleviating oxidative and mitochondrial stress. In murine models, the NPs treatment led to synergistic amelioration of steatosis, oxidative damage, and inflammation. Moreover, single‐cell transcriptomics demonstrated that the intervention suppresses fibrosis‐associated gene expression and reshapes the hepatic immune microenvironment. Collectively, our de novo AI‐designed peptide‐based nanotherapeutics presents a great potential for the precision treatment of MASH.

页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文

本页是 AI 精读,不转载论文原文;完整论文(含方法、图表与参考文献)见原文

来源:Advanced Functional Materials · doi.org